Description: Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies. Pure Biologics S.A. was incorporated in 2010 and is headquartered in Wroclaw, Poland.
Home Page: purebiologics.com
ul. Dunska 11
Wroclaw,
54-427
Poland
Phone:
48 795 61 18 11
Officers
| Name | Title |
|---|---|
| Dr. Filip Jelen M.B.A., Ph.D. | Co-founder & President of the Management Board |
| Mr. Romuald Apollo Harwas | CFO & Member of the Management Board |
| Dr. Pieter Spee | Chief Scientific Officer & Member of the Management Board |
| Mr. Przemyslaw Dudek | Head of Information Technology |
| Dr. Ewelina Swiderek Ph.D. | Head of Project Management |
Exchange: STU
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5232 |
| Price-to-Sales TTM: | 154.5864 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |